Ampio: Ampion reduces all-cause mortality in COVID-19 respiratory distress by nearly 80%

Ampio: Ampion reduces all-cause mortality in COVID-19 respiratory distress by nearly 80%

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a... Read More

Wednesday April 28, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, Michael Macaluso

Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects

Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced findings of pre-clinical research demonstrating Ampio's lead drug candidate, Ampion, provides some of the same anti-inflammatory... Read More

Tuesday April 20, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Dr. David Bar-Or, Michael Macaluso

Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress

Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in... Read More

Wednesday March 17, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, COVID-19, Michael Macaluso

Ampio provides update on clinical trials for Ampion treatment of COVID-19

Ampio provides update on clinical trials for Ampion treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced an update on the launch of a new global clinical trial for intravenous treatment of COVID-19 with Ampion and provided updates... Read More

Tuesday January 5, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, COVID-19

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More

Friday December 4, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, COVID-19, Inhaled Ampion

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the second group in the Phase I inhaled Ampionclinical study is being treated following clearance by the Safety Monitoring... Read More

Wednesday November 11, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, Michael Macaluso, COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hasbegun recruiting and enrolling patients in a Phase Imulti-center, randomized, controlled trial for a total of 40... Read More

Thursday October 29, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, Michael Macaluso

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it was featured on aFOXTV segment titled, "Englewoodpharmaceutical company looking to treat COVID-19 patients with... Read More

Friday April 3, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA, COVID-19, ARDS